Thalidomide: Therapeutic potential in hematologic malignancies

Seminars in Hematology

Volumn 37, Issue 1 SUPPL. 3, 2000, Pages 1-4

  Anderson, Kenneth C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; THALIDOMIDE; VASCULOTROPIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE REPORT; DRUG INDICATION; ERYTHEMA NODOSUM LEPROSUM; FEMALE; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

EID: 0034116011     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(00)90076-3     Document Type: Article

References (27)

1. KC Andersen TJ Hamblin A Traynor Management of multiple myeloma today Semin Hematol 36 1999 3 8 (suppl 3)
2. F Stevenson KC Anderson Introduction: Immunotherapy for multiple myeloma—Insights and advances Semin Hematol 36 1999 1 2 (suppl 3)
3. Y-W Huang A Hamilton OJ Arnuk Current drug therapy for multiple myeloma Drugs 57 1999 485 506
4. AR Perez-Atayde SE Sallan U Tedrow Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia Am J Pathol 150 1997 815 821
5. D Ribatti A Vacca B Nico Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma Br J Cancer 79 1999 451 455
6. A Vacca D Ribatti L Roncali Bone marrow angiogenesis and progression in multiple myeloma Br J Haematol 87 1994 503 508
7. J Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27 31
8. A Vacca M Di Loreto D Ribatti Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44 Am J Hematol 50 1995 9 14
9. N Munshi CS Wilson J Penn Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies Blood 92 suppl 1 1998 98a abstr
10. SV Rajkumar R Fonseca TE Witzig Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma Leukemia 13 1999 469 472
11. A Vacca D Ribatti M Presta Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma Blood 93 1999 3064 3073
12. BF Hales Thalidomide on the comeback trial Nat Med 5 1999 489 490
13. ™: A comprehensive program for controlling and monitoring access to thalidomide Clin Ther 21 1999 319 330
14. DI Stirling Thalidomide and its impact in dermatology Semin Cutan Med Surg 17 1998 231 242
15. RJ D'Amato MS Loughnan E Flynn Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 1994 4082 4085
16. BM Kenyon F Browne RJ D'Amato Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization Eye Res 64 1997 971 978
17. KS Bauer SC Dixon WD Figg Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent Biochem Pharmacol 55 1998 1827 1834
18. T Eisen C Boshoff MM Vaughan Antiangiogenic treatment of metastatic melanoma, renalcell, ovarian and breast cancers with a thalidomide: A phase II study Proc Am Soc Clin Oncol 17 1998 441a (abstr)
19. WD Figg R Bergan O Brawley Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC) Proc Am Soc Clin Oncol 16 1997 333a (abstr)
20. HA Fine JS Loeffler A Kyritsis A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas Proc Am Soc Clin Oncol 16 1997 385a (abstr)
21. G Long J Vredenburgh DA Rizzieri Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation (PBPC) in patients with metastatic breast cancer Proc Am Soc Clin Oncol 17 1998 181a (abstr)
22. GM Marx JA Levi DR Bell A phase I/II trial of thalidomide as an antiangiogenic agent in the treatment of advanced cancer Proc Am Soc Clin Oncol 18 1999 454a (abstr)
23. H Geitz S Handt K Zwingenberger Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade Immunopharmacology 31 1996 213 221
24. EP Sampaio G Kaplan A Miranda The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum J Infect Dis 168 1993 408 414
25. AC Nogueira R Neubert H Helge Thalidomide and the immune system 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells Life Sci 55 1994 77 92
26. + cells in the peripheral blood Lepr Rev 63 1992 5 11
27. S Singhal J Mehta P Eddlemon Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM) Blood 92 suppl 1 1998 318a abstr